WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001022983) VISCOSITY MODULATING SUBSTANCE AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/022983    International Application No.:    PCT/US2000/025874
Publication Date: 05.04.2001 International Filing Date: 21.09.2000
Chapter 2 Demand Filed:    18.04.2001    
IPC:
A61K 38/05 (2006.01)
Applicants: OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 NE 13th Street, Oklahoma City, OK 73104 (US) (For All Designated States Except US).
MANION, Carl, V. [US/US]; (US) (For US Only)
Inventors: MANION, Carl, V.; (US)
Agent: HANSEN, Eugenia, S.; Sidley & Austin Brown & Wood, Suite 3400, 717 North Harwood, Dallas, TX 75201 (US)
Priority Data:
60/156,119 25.09.1999 US
Title (EN) VISCOSITY MODULATING SUBSTANCE AND USE THEREOF
(FR) SUBSTANCE REGULATRICE DE VISCOSITE ET UTILISATION DE CELLE-CI
Abstract: front page image
(EN)It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patients, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment, patients experienced a significant lowering of whole blood viscosity. In vitro addition of APM to patients samples having elevated whole blood viscosity resulted in reduced viscosity over time. These in vitro and in vivo results identify APM as a therapeutic agent for molecular diseases which lead to elevated whole blood viscosity. A method by which APM treatment can be monitored is also disclosed.
(FR)On a découvert que N-L-alpha-aspartyl-L-phénylalanine 1-méthyl ester (APM) abaisse la viscosité sanguine totale chez des patients, y compris ceux qui souffrent de drépanocytose et de dysglobulinémie plasmocytaire. Lors d'un traitement à l'APM in vivo, on a constaté chez des patients une baisse significative de la viscosité sanguine totale. L'ajout in vitro d'APM dans des prélèvements de patients présentant une viscosité sanguine totale élevée a entraîné une réduction de cette viscosité au fil du temps. Ces résultats in vitro et in vivo montrent qu'APM est un agent thérapeutique destiné à des maladies moléculaires qui induisent une élévation de la viscosité sanguine totale. Cette invention concerne aussi une technique permettant de surveiller le traitement à l'APM.
Designated States: AU, CA, MX, US.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)